|
WO1993013101A1
(fr)
|
1991-12-27 |
1993-07-08 |
Yoshitomi Pharmaceutical Industries, Ltd. |
Compose de pyridonecarboxylate, son utilisation pharmaceutique et compose spiro
|
|
WO1998017276A1
(en)
|
1996-10-25 |
1998-04-30 |
Merck & Co., Inc. |
Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
|
|
US7319104B2
(en)
|
2002-03-01 |
2008-01-15 |
Smithkline Beecham Corporation |
hPPARs activators
|
|
TWI329111B
(en)
|
2002-05-24 |
2010-08-21 |
X Ceptor Therapeutics Inc |
Azepinoindole and pyridoindole derivatives as pharmaceutical agents
|
|
WO2004046162A2
(en)
|
2002-11-14 |
2004-06-03 |
The Scripps Research Institute |
Non-steroidal fxr agonists
|
|
WO2006006490A1
(ja)
|
2004-07-08 |
2006-01-19 |
Ono Pharmaceutical Co., Ltd. |
スピロ化合物
|
|
PL2402002T3
(pl)
|
2005-04-08 |
2018-11-30 |
Ptc Therapeutics, Inc. |
Kompozycje zawierające kwas 1,2,4-oksadiazolobenzoesowy i ich zastosowania do leczenia chorób związanych z przedwczesnym kodonem stop
|
|
WO2007076260A2
(en)
|
2005-12-19 |
2007-07-05 |
Smithkline Beecham Corporation |
Farnesoid x receptor agonists
|
|
WO2008011130A2
(en)
|
2006-07-21 |
2008-01-24 |
Takeda Pharmaceutical Company Limited |
Amide compounds
|
|
CL2007003035A1
(es)
|
2006-10-24 |
2008-05-16 |
Smithkline Beechman Corp |
Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
|
|
EP2108017A2
(en)
|
2007-01-30 |
2009-10-14 |
Biogen Idec MA, Inc. |
Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists
|
|
AU2008223348A1
(en)
|
2007-03-07 |
2008-09-12 |
Alantos Pharmaceuticals Holding, Inc. |
Metalloprotease inhibitors containing a heterocyclic moiety
|
|
MX2009013946A
(es)
|
2007-07-02 |
2010-03-10 |
Glaxosmithkline Llc |
Agonistas del receptor de farnesoide x.
|
|
WO2009009059A1
(en)
|
2007-07-09 |
2009-01-15 |
Biogen Idec Ma Inc. |
Spiro compounds as antagonists of tgf-beta
|
|
TW200906823A
(en)
|
2007-07-16 |
2009-02-16 |
Lilly Co Eli |
Compounds and methods for modulating FXR
|
|
CN101910151A
(zh)
|
2007-10-22 |
2010-12-08 |
先灵公司 |
双环杂环衍生物及其作为gpr119活性调节剂的用途
|
|
EP2128158A1
(en)
|
2008-05-26 |
2009-12-02 |
Phenex Pharmaceuticals AG |
Heterocyclic cyclopropyl-substituted FXR binding compounds
|
|
US20110230493A1
(en)
|
2008-11-21 |
2011-09-22 |
Pfizer Inc. |
1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors
|
|
EP2454243A2
(en)
|
2009-07-15 |
2012-05-23 |
Merck Serono SA |
Tetrazole derivatives
|
|
US8440710B2
(en)
|
2009-10-15 |
2013-05-14 |
Hoffmann-La Roche Inc. |
HSL inhibitors useful in the treatment of diabetes
|
|
EP2655368A1
(en)
|
2010-12-20 |
2013-10-30 |
Irm Llc |
Compositions and methods for modulating farnesoid x receptors
|
|
CU24152B1
(es)
|
2010-12-20 |
2016-02-29 |
Irm Llc |
1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
|
|
EP2545964A1
(en)
|
2011-07-13 |
2013-01-16 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
|
IN2014DN09346A
(https=)
|
2012-06-13 |
2015-07-17 |
Hoffmann La Roche |
|
|
EP2903985A1
(en)
|
2012-10-03 |
2015-08-12 |
Advinus Therapeutics Limited |
Spirocyclic compounds, compositions and medicinal applications thereof
|
|
US9567301B2
(en)
|
2012-11-02 |
2017-02-14 |
Dana-Farber Cancer Institute, Inc. |
Pyrrol-1-yl benzoic acid derivatives useful as myc inhibitors
|
|
WO2014113485A1
(en)
|
2013-01-15 |
2014-07-24 |
Intermune, Inc. |
Lysophosphatidic acid receptor antagonists
|
|
JP6333372B2
(ja)
|
2013-07-09 |
2018-05-30 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｃ型肝炎ウイルス阻害剤の組み合わせ
|
|
EP3116851B1
(en)
*
|
2014-03-13 |
2023-07-26 |
Salk Institute for Biological Studies |
Analogs of fexaramine and methods of making and using
|
|
WO2015172747A1
(en)
|
2014-05-16 |
2015-11-19 |
Zhaoyin Wang |
Spirocyclic molecules as mth1 inhibitors
|
|
WO2016039734A1
(en)
|
2014-09-10 |
2016-03-17 |
Halliburton Energy Services, Inc. |
Perforating gun with integrated retaining system
|
|
EP3034499A1
(en)
|
2014-12-17 |
2016-06-22 |
Gilead Sciences, Inc. |
Novel FXR (NR1H4) modulating compounds
|
|
EP3034501A1
(en)
|
2014-12-17 |
2016-06-22 |
Gilead Sciences, Inc. |
Hydroxy containing FXR (NR1H4) modulating compounds
|
|
MX2017008057A
(es)
|
2014-12-18 |
2017-09-28 |
Novartis Ag |
Derivados de azabiciclooctano como agonistas de fxr para el uso en el tratamiento de enfermedades hepaticas y gastrointestinales.
|
|
CN106146483A
(zh)
|
2015-04-23 |
2016-11-23 |
上海迪诺医药科技有限公司 |
杂环类法尼酯衍生物x受体调节剂
|
|
EP3350164A4
(en)
*
|
2015-09-16 |
2019-03-27 |
Metacrine, Inc. |
FARNESOID-X RECEPTOR AGONISTS AND USES THEREOF
|
|
US10703712B2
(en)
*
|
2015-09-16 |
2020-07-07 |
Metacrine, Inc. |
Farnesoid X receptor agonists and uses thereof
|
|
WO2017078927A1
(en)
|
2015-11-06 |
2017-05-11 |
Salk Institute For Biological Studies |
Analogs of fexaramine and methods of making and using
|
|
CN106946867B
(zh)
|
2016-01-06 |
2019-11-12 |
广州市恒诺康医药科技有限公司 |
Fxr受体调节剂及其制备方法和用途
|
|
CN107021958A
(zh)
|
2016-02-01 |
2017-08-08 |
山东轩竹医药科技有限公司 |
Fxr受体激动剂
|
|
WO2017133521A1
(zh)
|
2016-02-01 |
2017-08-10 |
山东轩竹医药科技有限公司 |
Fxr受体激动剂
|
|
MX384205B
(es)
|
2016-02-22 |
2025-03-14 |
Novartis Ag |
Metodos para usar agonistas de fxr.
|
|
ES2862194T3
(es)
|
2016-02-22 |
2021-10-07 |
Novartis Ag |
Métodos para usar agonistas del FXR
|
|
CN109640987B
(zh)
|
2016-03-16 |
2022-12-02 |
库拉肿瘤学公司 |
Menin-mll的桥联双环抑制剂及使用方法
|
|
WO2017189651A1
(en)
|
2016-04-26 |
2017-11-02 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
WO2017189663A1
(en)
|
2016-04-26 |
2017-11-02 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
US10080741B2
(en)
|
2016-04-26 |
2018-09-25 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as FXR agonists and methods of use thereof
|
|
WO2017201155A1
(en)
|
2016-05-18 |
2017-11-23 |
Enanta Pharmaceuticals, Inc. |
lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
|
|
AR108711A1
(es)
|
2016-06-13 |
2018-09-19 |
Gilead Sciences Inc |
Compuestos moduladores de fxr (nr1h4)
|
|
MX385718B
(es)
|
2016-06-13 |
2025-03-18 |
Gilead Sciences Inc |
Compuestos moduladores de fxr (nr1h4).
|
|
CN108430998B
(zh)
|
2016-09-28 |
2021-07-09 |
四川科伦博泰生物医药股份有限公司 |
氮杂双环衍生物及其制备方法和用途
|
|
CN106632294A
(zh)
|
2016-12-15 |
2017-05-10 |
宁波百纳西药业有限公司 |
一种螺环化合物及其药物用途
|
|
WO2018170165A1
(en)
*
|
2017-03-15 |
2018-09-20 |
Metacrine, Inc. |
Farnesoid x receptor agonists and uses thereof
|
|
WO2018170167A1
(en)
|
2017-03-15 |
2018-09-20 |
Metacrine, Inc. |
Farnesoid x receptor agonists and uses thereof
|
|
US20200131129A1
(en)
|
2017-03-15 |
2020-04-30 |
Metacrine, Inc. |
Farnesoid x receptor agonists and uses thereof
|
|
CA3055990A1
(en)
*
|
2017-03-15 |
2018-09-20 |
Metacrine, Inc. |
Farnesoid x receptor agonists and uses thereof
|
|
JP7258763B2
(ja)
*
|
2017-03-15 |
2023-04-17 |
メタクリン，インク． |
ファルネソイドｘ受容体アゴニストおよびその使用
|
|
PE20201170A1
(es)
|
2017-11-01 |
2020-10-28 |
Bristol Myers Squibb Co |
Compuestos biciclicos en puente como moduladores del receptor farnesoide x
|
|
EA202190661A1
(ru)
|
2018-09-18 |
2021-08-13 |
Метакрайн, Инк. |
Агонисты фарнезоидного х-рецептора для лечения заболевания
|